医药行业分析
- (2024-04-02)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-04-01)
- (2024-03-31)
- (2024-03-31)
- (2024-03-30)
- (2024-03-30)
- (2024-03-30)
- (2024-03-30)
- (2024-03-29)
- (2024-03-29)
- (2024-03-29)
- (2024-03-29)
- (2024-03-29)
- (2024-03-29)
- (2024-03-29)
- (2024-03-28)
- (2024-03-28)
- (2024-03-28)
- (2024-03-28)
- (2024-03-28)
- (2024-03-28)
- (2024-03-28)
- (2024-03-28)
- (2024-03-27)
- (2024-03-27)
- (2024-03-27)
- (2024-03-27)
- (2024-03-27)
- (2024-03-27)
- (2024-03-27)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
广生堂一类创新药泰中定—超级3CL抑制剂的注册临床研究数据将发表于国际权威医学期刊柳叶刀《eClinicalMedicine》
(2024-03-26)- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)
- (2024-03-26)